Piper Jaffray analyst, Joshua Schimmer, noted that after the close, Alexion Pharmaceuticals (NASDAQ: ALXN) reported topline results from Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE